(Q37707415)

22 August 2017

1 reference

title

Lipoprotein-associated phospholipase A2: role in atherosclerosis and utility as a cardiovascular biomarker (English)

1 reference

22 August 2017

0 references

1 reference

1 reference

1 reference

1

Peter P Toth

1 reference

22 August 2017

Peter A McCullough

2

1 reference

22 August 2017

Michael S Wegner

series ordinal

3

1 reference

22 August 2017

Kenneth J Colley

series ordinal

4

1 reference

22 August 2017

publication date

1 March 2010

1 reference

Expert Review of Cardiovascular Therapy

22 August 2017

published in

1 reference

22 August 2017

volume

8

1 reference

22 August 2017

issue

3

1 reference

22 August 2017

page(s)

425-438

1 reference

Making a case for quantitative assessment of cardiovascular risk

22 August 2017

cites work

1 reference

Clinical application of C-reactive protein for cardiovascular disease detection and prevention

21 January 2018

1 reference

A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women

21 January 2018

1 reference

Myeloperoxidase and cardiovascular disease.

21 January 2018

1 reference

Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency

21 January 2018

1 reference

Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications

21 January 2018

1 reference

C-reactive protein and risk of cardiovascular disease: evidence and clinical application

21 January 2018

1 reference

Emerging role of myeloperoxidase and oxidant stress markers in cardiovascular risk assessment

21 January 2018

1 reference

Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study

21 January 2018

1 reference

Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study

21 January 2018

1 reference

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

21 January 2018

1 reference

21 January 2018

The C-reactive protein

1 reference

Adipokines: molecular links between obesity and atheroslcerosis

21 January 2018

1 reference

Narrative review: Assessment of C-reactive protein in risk prediction for cardiovascular disease

21 January 2018

1 reference

The effect of weight loss on C-reactive protein: a systematic review

21 January 2018

1 reference

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

A randomized trial of rosuvastatin in the prevention of venous thromboembolism

21 January 2018

1 reference

Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER).

21 January 2018

1 reference

C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease

21 January 2018

1 reference

Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores

21 January 2018

1 reference

Genetically elevated C-reactive protein and ischemic vascular disease

21 January 2018

1 reference

Targeting C-reactive protein for the treatment of cardiovascular disease.

21 January 2018

1 reference

C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus

21 January 2018

1 reference

Myeloperoxidase: friend and foe

21 January 2018

1 reference

Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes

21 January 2018

1 reference

Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions

21 January 2018

1 reference

Increased atherosclerosis in myeloperoxidase-deficient mice

21 January 2018

1 reference

Biosynthesis, processing, and sorting of human myeloperoxidase

21 January 2018

1 reference

Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease

21 January 2018

1 reference

Prognostic value of myeloperoxidase in patients with chest pain

21 January 2018

1 reference

Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study

21 January 2018

1 reference

Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction

21 January 2018

1 reference

Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker

21 January 2018

1 reference

Lipoprotein-associated phospholipase A2: a cardiovascular risk predictor and a potential therapeutic target

21 January 2018

1 reference

Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques

21 January 2018

1 reference

Relationship of lipoprotein-associated phospholipase A2 and oxidized low density lipoprotein in carotid atherosclerosis.

21 January 2018

1 reference

Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target

21 January 2018

1 reference

Lipoprotein-associated phospholipase A2, hormone use, and the risk of ischemic stroke in postmenopausal women

21 January 2018

1 reference

High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke

21 January 2018

1 reference

Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up

21 January 2018

1 reference

Novel and conventional biomarkers for prediction of incident cardiovascular events in the community

21 January 2018

1 reference

Use and misuse of the receiver operating characteristic curve in risk prediction

21 January 2018

1 reference

Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study

21 January 2018

1 reference

Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines

21 January 2018

1 reference

Lipoprotein-associated phospholipase A2: review and recommendation of a clinical cut point for adults

21 January 2018

1 reference

Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome

21 January 2018

1 reference

Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease.

21 January 2018

1 reference

The effect of statin therapy on lipoprotein associated phospholipase A2 levels

21 January 2018

1 reference

Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development

21 January 2018

1 reference

Darapladib and atherosclerotic plaque: should lipoprotein-associated phospholipase A2 be a therapeutic target?

21 January 2018

1 reference

The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, dou

21 January 2018

1 reference

Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque

21 January 2018

1 reference

C-reactive protein and cardiovascular disease: weighing the evidence

21 January 2018

1 reference

Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern G

21 January 2018

1 reference

Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERC.10.18

1 reference

22 August 2017

1 reference